<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648100</url>
  </required_header>
  <id_info>
    <org_study_id>NI 13021</org_study_id>
    <nct_id>NCT02648100</nct_id>
  </id_info>
  <brief_title>Basal Like Bladder Cancer : Signature and Therapeutic</brief_title>
  <acronym>DIATRIBBE</acronym>
  <official_title>Identification and Treatments of Basal Like Bladder Cancer (Study on Human Tumor Samples and Animal Models)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paris 12 Val de Marne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscle invasive (MIBC) and/or metastatic bladder cancer is associated with poor prognosis and
      no target therapies for this pathology are currently validated. By 40 gene expression
      signature realized on frozen samples, we have previously identified an aggressive sub-class
      of MIBC, called basal. This sub-class (20% of MIBC) showed strong EGFR dependence in vitro
      and in vivo (Rebouissou et al. Science Translational Medicine 2014). This observation
      suggests a possible response to EGFR targeted therapy in patients of this subgroup. Our aim
      is to establish a standard diagnostic tool to differentiate the basal subtype of bladder
      cancer and evaluate the effect of anti-EGFR therapy, by analyzing previous clinical trial
      (GETUG19) and preclinical models, which compare the classical chemotherapy to anti-EGFR
      associated chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is:

        1. To validate a diagnostic test for formalin-fixed paraffin-embedded (FFPE) samples by
           Nanostring technology, using the 40 genes signature as reference. First, we will compare
           frozen and FFPE tissues (n=120), to establish a transcriptional signature in FFPE
           samples. Secondly, to further characterize basal subtype of bladder cancer, we will
           study the mutational and gain/loss landscape and immunohistochemistry markers in a new
           series of tumors after classifying them by our gene signature (n=510). These
           characteristics will be included in a new signature by defining the optimal prediction
           discrimination AIC et Net Reclassification Index.

        2. To assess the prognosis after cisplatine treatment in 510 patients treated by cystectomy
           with or without adjuvant chemotherapy (pT2/pT3/pT4, N0 or N+) and in another
           multicentric series of 188 patients treated by cystectomy and adjuvant chemotherapy
           (pT3/pT4 et/ou N+). Uni and multi variant analysis will be realized by adjusted Cox
           model, and the added value of basal subtype as compared to standard prognostic factors
           will be evaluated. The propensity score will be realized to assess the association of
           basal subtype and response to chemotherapy. The anti-EGFR response will be analyzed in
           the clinical trial GETUG19 which uses Panitumumab in patients with metastatic urothelial
           carcinomas (n=93)

        3. To study the treatment response in preclinical models. We characterized previously
           preclinical murine models derived from xenografts of MIBC (n=14 and new xenografts will
           be added). We will study the effect of anti-EGFR alone or in combination with
           chemotherapy in basal and non basal subtypes of xenografts.

      By this study we will be able to better characterize the basal subtype of bladder cancer and
      confirm its aggressive behaviour as compared to other subtypes of MIBC. These results will
      further help to establish new clinical trials which include anti-EGFR in patients of basal
      subtype.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">911</enrollment>
  <condition>Muscle Invasive Bladder Cancer</condition>
  <condition>Molecular Taxonomy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <description>93 patients from the clinical trial GETUG 19 (UNICANCER)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarker study</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue : frozen (n=120), FFPE (n=911)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Bladder Cancer from 4 cohorts

          -  2 observational cohorts of patients with muscle invasive bladder cancer (all stages)
             from two Henri Mondor (Créteil) and Foch (Suresnes) hospitals

          -  1 multicentric observational cohort of patients with locally advanced muscle invasive
             bladder cancer trated by adjuvantchemotherapy after cystectomy

          -  1 clinical trial GETUG 19 (MVAC + panitumumab)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Muscle invasive bladder cancer Treatment by cystectomy Adjuvant chemotherapy for 3rd cohort
        Clinical trial GETUG 19 for 4th cohort

        Exclusion Criteria:

        FFPE material not available Follow-up data not available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves ALLORY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves ALLORY, MD, PhD</last_name>
    <phone>(0)1 49 81 27 29</phone>
    <phone_ext>+33</phone_ext>
    <email>yves.allory@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François RADVANYI, PhD</last_name>
    <phone>(0)1 42 34 63 39</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.radvanyi@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle invasive bladder cancer</keyword>
  <keyword>Basal subtype</keyword>
  <keyword>Anti-EGFR treatment</keyword>
  <keyword>Nanostring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

